Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17965655 | 0.98 | CYP19A1 (0.64) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL22063794 | 0.98 | CYP19A1 (0.64) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL18135002 | 0.98 | CYP19A1 (0.64) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL29354558 | 0.94 | CYP19A1 (0.55) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL17449597 | 0.94 | CYP19A1 (0.55) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL12928016 | 0.89 | CYP19A1 (0.51) | CYP19A1P2RX4MEN1KMT2AMAPT | |
| SCHEMBL12928019 | 0.89 | CYP19A1 (0.51) | CYP19A1P2RX4MEN1KMT2AMAPT | |
| SCHEMBL23774553 | 0.88 | CYP19A1 (0.58) | CYP19A1P2RX4SRCMEN1KMT2A | |
| SCHEMBL12928014 | 0.88 | CYP19A1 (0.50) | CYP19A1P2RX4MEN1KMT2AMAPT | |
| SCHEMBL18134997 | 0.86 | CYP19A1 (0.49) | CYP19A1P2RX4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3053910-B1 | ANILINE DERIVATIVES AND USES THEREOF | NISSAN CHEMICAL CORP (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-3109914-B1 | CHARGE-TRANSPORTING VARNISH | NISSAN CHEMICAL CORP (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10700283-B2 | Aniline derivatives and uses thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3109914-A1 | CHARGE-TRANSPORTING VARNISH | Nissan Chemical Industries, Ltd. (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20160301011-A1 | ANILINE DERIVATIVES AND USES THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-13 | — | — | US | disclosed |
| EP-3053910-A1 | ANILINE DERIVATIVES AND USES THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160301011-A1 | ANILINE DERIVATIVES AND USES THEREOF | SLC18A1, SLC18A2, SLC43A1 | CYP19A1 475/4885P2RX4 372/4885SRC 3643/4885 |
| US-10700283-B2 | Aniline derivatives and uses thereof | SLC18A1, SLC18A2, SLC43A1 | CYP19A1 475/4885P2RX4 372/4885SRC 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.